In the BioHarmony Drug Report Database

"Preview" Icon

Ribociclib

Kisqali (ribociclib) is a small molecule pharmaceutical. Ribociclib was first approved as Kisqali on 2017-03-13. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against cyclin-dependent kinase 4. Kisqali’s patents are valid until 2036-04-14 (FDA).

 

Trade Name

 

Kisqali
 

Common Name

 

ribociclib
 

ChEMBL ID

 

CHEMBL3545110
 

Indication

 

breast neoplasms
 

Drug Class

 

Cyclin dependent kinase inhibitors

Image (chem structure or protein)

Ribociclib structure rendering